PHARM RES-DORDR 润色咨询

PHARMACEUTICAL RESEARCH

出版年份：1984 年文章数：5840 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：3.9% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1099272, encodeId=697010992e2ce, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854040, encodeId=18ce854040d2, content=药剂学方向，纳米胶束。<br> 文章创新性自我感觉不足，但是做的比较全面，四个审稿人意见都比较正面，一审四个审稿人，三个问题不大，reviewer4问题较多，一一解答并且修改，补了几个小实验，10天后修回。二审editor提了几点意见，重点说语言，两个审稿人没啥意见。找国外的朋友改了改。花了17天修改语言，修回后第二天直接接受，总共历时三个月，其中修稿差不多一个月，效率还可以。<br> 总结下：总共历时三个月。审稿人比较友好，提的问题也不难为人，编辑态度友好，编辑部效率较高，主要时间都花在了审稿上，二审时间较长。<br> 6.28 submitted<br> 6.28 editor assigned<br> 7.11 under review<br> 8.4 major revision<br> 8.15 submitted revised manuscript<br> 8.15 under review<br> 9.11 minor revision<br> 9.28 submitted revised manuscript<br> 9.29 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Mon Sep 30 10:37:18 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099271, encodeId=abfb10992e13b, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587723, encodeId=775458e7232a, content=请问这个杂志收费吗<span class="quote">zjqrae01 2014-07-09 13:33:00 发表:<br>今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。</span>, beContent=zjqrae01 2014-07-09 13:33:00 发表: 今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b195095115, createdName=145e0123m82暂无昵称, createdTime=Sun Mar 29 00:00:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854503, encodeId=bcfe8545033e, content=7.4 submitted<br> 8.25 major revision<br> 9.19 minor revision<br> 9.24 accepted<br> 两个审稿人，问题有点多，加编辑部指出一些语言方面的问题，总体感觉很友好。美国药学科学家协会的官方杂志之一，希望if稳定。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad75414098, createdName=ms658988217505615, createdTime=Fri Oct 25 19:52:53 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539451, encodeId=bc335394517c, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833325, encodeId=afcf833325da, content=速度很快，四十天就解决了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Aug 22 23:05:49 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504008, encodeId=ce2b50400880, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=529, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f06c87693, createdName=zjqrae01, createdTime=Wed Jul 09 13:33:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503302, encodeId=205e50330207, content=刚刚接受一篇，大修后主编直接接受！感觉主编、编辑、专家都很认真，很懂，提了很多问题一起探讨，是药剂学领域比较不错的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=463, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jun 03 10:39:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502240, encodeId=1d56502240cd, content=曾发过1篇 <br> <br> 俺不久前（其实“不久”也就一年）再次投稿这个杂志 <br> 近2个月后，两个Reviewers 一正一反 <br> 主编也不找仲裁 让俺大改 <br> 俺就大改回投 （1个月） <br> 3个月后，我发邮件询问二婶结果 主编说请耐心给他们一些时间 <br> 再过1个月 拒稿信件里面是唱反Reviewer的固执 <br> 外加主编的胡扯“我看稿件质量也一般，非常欢迎你下次再来搞”！ <br> <br> 我入，被这帮孙子搞晕了！ <br> 再也不跟他们玩了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:42:00 CST 2014, time=2014-04-08, status=1, ipAttribution=)]
    2021-12-29 学医的彭于晏

    是否需要在讨论中说明文章局限性？

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1099272, encodeId=697010992e2ce, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854040, encodeId=18ce854040d2, content=药剂学方向，纳米胶束。<br> 文章创新性自我感觉不足，但是做的比较全面，四个审稿人意见都比较正面，一审四个审稿人，三个问题不大，reviewer4问题较多，一一解答并且修改，补了几个小实验，10天后修回。二审editor提了几点意见，重点说语言，两个审稿人没啥意见。找国外的朋友改了改。花了17天修改语言，修回后第二天直接接受，总共历时三个月，其中修稿差不多一个月，效率还可以。<br> 总结下：总共历时三个月。审稿人比较友好，提的问题也不难为人，编辑态度友好，编辑部效率较高，主要时间都花在了审稿上，二审时间较长。<br> 6.28 submitted<br> 6.28 editor assigned<br> 7.11 under review<br> 8.4 major revision<br> 8.15 submitted revised manuscript<br> 8.15 under review<br> 9.11 minor revision<br> 9.28 submitted revised manuscript<br> 9.29 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Mon Sep 30 10:37:18 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099271, encodeId=abfb10992e13b, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587723, encodeId=775458e7232a, content=请问这个杂志收费吗<span class="quote">zjqrae01 2014-07-09 13:33:00 发表:<br>今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。</span>, beContent=zjqrae01 2014-07-09 13:33:00 发表: 今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b195095115, createdName=145e0123m82暂无昵称, createdTime=Sun Mar 29 00:00:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854503, encodeId=bcfe8545033e, content=7.4 submitted<br> 8.25 major revision<br> 9.19 minor revision<br> 9.24 accepted<br> 两个审稿人，问题有点多，加编辑部指出一些语言方面的问题，总体感觉很友好。美国药学科学家协会的官方杂志之一，希望if稳定。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad75414098, createdName=ms658988217505615, createdTime=Fri Oct 25 19:52:53 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539451, encodeId=bc335394517c, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833325, encodeId=afcf833325da, content=速度很快，四十天就解决了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Aug 22 23:05:49 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504008, encodeId=ce2b50400880, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=529, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f06c87693, createdName=zjqrae01, createdTime=Wed Jul 09 13:33:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503302, encodeId=205e50330207, content=刚刚接受一篇，大修后主编直接接受！感觉主编、编辑、专家都很认真，很懂，提了很多问题一起探讨，是药剂学领域比较不错的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=463, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jun 03 10:39:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502240, encodeId=1d56502240cd, content=曾发过1篇 <br> <br> 俺不久前（其实“不久”也就一年）再次投稿这个杂志 <br> 近2个月后，两个Reviewers 一正一反 <br> 主编也不找仲裁 让俺大改 <br> 俺就大改回投 （1个月） <br> 3个月后，我发邮件询问二婶结果 主编说请耐心给他们一些时间 <br> 再过1个月 拒稿信件里面是唱反Reviewer的固执 <br> 外加主编的胡扯“我看稿件质量也一般，非常欢迎你下次再来搞”！ <br> <br> 我入，被这帮孙子搞晕了！ <br> 再也不跟他们玩了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:42:00 CST 2014, time=2014-04-08, status=1, ipAttribution=)]
    2019-09-30 ms3508121495608353

    药剂学方向，纳米胶束。
    文章创新性自我感觉不足，但是做的比较全面，四个审稿人意见都比较正面，一审四个审稿人，三个问题不大，reviewer4问题较多，一一解答并且修改，补了几个小实验，10天后修回。二审editor提了几点意见，重点说语言，两个审稿人没啥意见。找国外的朋友改了改。花了17天修改语言，修回后第二天直接接受，总共历时三个月，其中修稿差不多一个月，效率还可以。
    总结下：总共历时三个月。审稿人比较友好，提的问题也不难为人，编辑态度友好，编辑部效率较高，主要时间都花在了审稿上，二审时间较长。
    6.28 submitted
    6.28 editor assigned
    7.11 under review
    8.4 major revision
    8.15 submitted revised manuscript
    8.15 under review
    9.11 minor revision
    9.28 submitted revised manuscript
    9.29 accepted

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1099272, encodeId=697010992e2ce, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854040, encodeId=18ce854040d2, content=药剂学方向，纳米胶束。<br> 文章创新性自我感觉不足，但是做的比较全面，四个审稿人意见都比较正面，一审四个审稿人，三个问题不大，reviewer4问题较多，一一解答并且修改，补了几个小实验，10天后修回。二审editor提了几点意见，重点说语言，两个审稿人没啥意见。找国外的朋友改了改。花了17天修改语言，修回后第二天直接接受，总共历时三个月，其中修稿差不多一个月，效率还可以。<br> 总结下：总共历时三个月。审稿人比较友好，提的问题也不难为人，编辑态度友好，编辑部效率较高，主要时间都花在了审稿上，二审时间较长。<br> 6.28 submitted<br> 6.28 editor assigned<br> 7.11 under review<br> 8.4 major revision<br> 8.15 submitted revised manuscript<br> 8.15 under review<br> 9.11 minor revision<br> 9.28 submitted revised manuscript<br> 9.29 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Mon Sep 30 10:37:18 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099271, encodeId=abfb10992e13b, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587723, encodeId=775458e7232a, content=请问这个杂志收费吗<span class="quote">zjqrae01 2014-07-09 13:33:00 发表:<br>今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。</span>, beContent=zjqrae01 2014-07-09 13:33:00 发表: 今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b195095115, createdName=145e0123m82暂无昵称, createdTime=Sun Mar 29 00:00:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854503, encodeId=bcfe8545033e, content=7.4 submitted<br> 8.25 major revision<br> 9.19 minor revision<br> 9.24 accepted<br> 两个审稿人，问题有点多，加编辑部指出一些语言方面的问题，总体感觉很友好。美国药学科学家协会的官方杂志之一，希望if稳定。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad75414098, createdName=ms658988217505615, createdTime=Fri Oct 25 19:52:53 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539451, encodeId=bc335394517c, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833325, encodeId=afcf833325da, content=速度很快，四十天就解决了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Aug 22 23:05:49 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504008, encodeId=ce2b50400880, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=529, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f06c87693, createdName=zjqrae01, createdTime=Wed Jul 09 13:33:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503302, encodeId=205e50330207, content=刚刚接受一篇，大修后主编直接接受！感觉主编、编辑、专家都很认真，很懂，提了很多问题一起探讨，是药剂学领域比较不错的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=463, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jun 03 10:39:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502240, encodeId=1d56502240cd, content=曾发过1篇 <br> <br> 俺不久前（其实“不久”也就一年）再次投稿这个杂志 <br> 近2个月后，两个Reviewers 一正一反 <br> 主编也不找仲裁 让俺大改 <br> 俺就大改回投 （1个月） <br> 3个月后，我发邮件询问二婶结果 主编说请耐心给他们一些时间 <br> 再过1个月 拒稿信件里面是唱反Reviewer的固执 <br> 外加主编的胡扯“我看稿件质量也一般，非常欢迎你下次再来搞”！ <br> <br> 我入，被这帮孙子搞晕了！ <br> 再也不跟他们玩了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:42:00 CST 2014, time=2014-04-08, status=1, ipAttribution=)]
    2021-12-27 rayms

    文章的局限性是什么？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1099272, encodeId=697010992e2ce, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854040, encodeId=18ce854040d2, content=药剂学方向，纳米胶束。<br> 文章创新性自我感觉不足，但是做的比较全面，四个审稿人意见都比较正面，一审四个审稿人，三个问题不大，reviewer4问题较多，一一解答并且修改，补了几个小实验，10天后修回。二审editor提了几点意见，重点说语言，两个审稿人没啥意见。找国外的朋友改了改。花了17天修改语言，修回后第二天直接接受，总共历时三个月，其中修稿差不多一个月，效率还可以。<br> 总结下：总共历时三个月。审稿人比较友好，提的问题也不难为人，编辑态度友好，编辑部效率较高，主要时间都花在了审稿上，二审时间较长。<br> 6.28 submitted<br> 6.28 editor assigned<br> 7.11 under review<br> 8.4 major revision<br> 8.15 submitted revised manuscript<br> 8.15 under review<br> 9.11 minor revision<br> 9.28 submitted revised manuscript<br> 9.29 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Mon Sep 30 10:37:18 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099271, encodeId=abfb10992e13b, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587723, encodeId=775458e7232a, content=请问这个杂志收费吗<span class="quote">zjqrae01 2014-07-09 13:33:00 发表:<br>今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。</span>, beContent=zjqrae01 2014-07-09 13:33:00 发表: 今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b195095115, createdName=145e0123m82暂无昵称, createdTime=Sun Mar 29 00:00:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854503, encodeId=bcfe8545033e, content=7.4 submitted<br> 8.25 major revision<br> 9.19 minor revision<br> 9.24 accepted<br> 两个审稿人，问题有点多，加编辑部指出一些语言方面的问题，总体感觉很友好。美国药学科学家协会的官方杂志之一，希望if稳定。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad75414098, createdName=ms658988217505615, createdTime=Fri Oct 25 19:52:53 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539451, encodeId=bc335394517c, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833325, encodeId=afcf833325da, content=速度很快，四十天就解决了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Aug 22 23:05:49 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504008, encodeId=ce2b50400880, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=529, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f06c87693, createdName=zjqrae01, createdTime=Wed Jul 09 13:33:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503302, encodeId=205e50330207, content=刚刚接受一篇，大修后主编直接接受！感觉主编、编辑、专家都很认真，很懂，提了很多问题一起探讨，是药剂学领域比较不错的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=463, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jun 03 10:39:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502240, encodeId=1d56502240cd, content=曾发过1篇 <br> <br> 俺不久前（其实“不久”也就一年）再次投稿这个杂志 <br> 近2个月后，两个Reviewers 一正一反 <br> 主编也不找仲裁 让俺大改 <br> 俺就大改回投 （1个月） <br> 3个月后，我发邮件询问二婶结果 主编说请耐心给他们一些时间 <br> 再过1个月 拒稿信件里面是唱反Reviewer的固执 <br> 外加主编的胡扯“我看稿件质量也一般，非常欢迎你下次再来搞”！ <br> <br> 我入，被这帮孙子搞晕了！ <br> 再也不跟他们玩了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:42:00 CST 2014, time=2014-04-08, status=1, ipAttribution=)]
    2020-03-29 145e0123m82暂无昵称

    请问这个杂志收费吗zjqrae01 2014-07-09 13:33:00 发表:
    今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。

    zjqrae01 2014-07-09 13:33:00 发表: 今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1099272, encodeId=697010992e2ce, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854040, encodeId=18ce854040d2, content=药剂学方向，纳米胶束。<br> 文章创新性自我感觉不足，但是做的比较全面，四个审稿人意见都比较正面，一审四个审稿人，三个问题不大，reviewer4问题较多，一一解答并且修改，补了几个小实验，10天后修回。二审editor提了几点意见，重点说语言，两个审稿人没啥意见。找国外的朋友改了改。花了17天修改语言，修回后第二天直接接受，总共历时三个月，其中修稿差不多一个月，效率还可以。<br> 总结下：总共历时三个月。审稿人比较友好，提的问题也不难为人，编辑态度友好，编辑部效率较高，主要时间都花在了审稿上，二审时间较长。<br> 6.28 submitted<br> 6.28 editor assigned<br> 7.11 under review<br> 8.4 major revision<br> 8.15 submitted revised manuscript<br> 8.15 under review<br> 9.11 minor revision<br> 9.28 submitted revised manuscript<br> 9.29 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Mon Sep 30 10:37:18 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099271, encodeId=abfb10992e13b, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587723, encodeId=775458e7232a, content=请问这个杂志收费吗<span class="quote">zjqrae01 2014-07-09 13:33:00 发表:<br>今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。</span>, beContent=zjqrae01 2014-07-09 13:33:00 发表: 今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b195095115, createdName=145e0123m82暂无昵称, createdTime=Sun Mar 29 00:00:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854503, encodeId=bcfe8545033e, content=7.4 submitted<br> 8.25 major revision<br> 9.19 minor revision<br> 9.24 accepted<br> 两个审稿人，问题有点多，加编辑部指出一些语言方面的问题，总体感觉很友好。美国药学科学家协会的官方杂志之一，希望if稳定。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad75414098, createdName=ms658988217505615, createdTime=Fri Oct 25 19:52:53 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539451, encodeId=bc335394517c, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833325, encodeId=afcf833325da, content=速度很快，四十天就解决了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Aug 22 23:05:49 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504008, encodeId=ce2b50400880, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=529, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f06c87693, createdName=zjqrae01, createdTime=Wed Jul 09 13:33:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503302, encodeId=205e50330207, content=刚刚接受一篇，大修后主编直接接受！感觉主编、编辑、专家都很认真，很懂，提了很多问题一起探讨，是药剂学领域比较不错的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=463, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jun 03 10:39:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502240, encodeId=1d56502240cd, content=曾发过1篇 <br> <br> 俺不久前（其实“不久”也就一年）再次投稿这个杂志 <br> 近2个月后，两个Reviewers 一正一反 <br> 主编也不找仲裁 让俺大改 <br> 俺就大改回投 （1个月） <br> 3个月后，我发邮件询问二婶结果 主编说请耐心给他们一些时间 <br> 再过1个月 拒稿信件里面是唱反Reviewer的固执 <br> 外加主编的胡扯“我看稿件质量也一般，非常欢迎你下次再来搞”！ <br> <br> 我入，被这帮孙子搞晕了！ <br> 再也不跟他们玩了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:42:00 CST 2014, time=2014-04-08, status=1, ipAttribution=)]
    2019-10-25 ms658988217505615

    7.4 submitted
    8.25 major revision
    9.19 minor revision
    9.24 accepted
    两个审稿人，问题有点多，加编辑部指出一些语言方面的问题，总体感觉很友好。美国药学科学家协会的官方杂志之一，希望if稳定。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1099272, encodeId=697010992e2ce, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854040, encodeId=18ce854040d2, content=药剂学方向，纳米胶束。<br> 文章创新性自我感觉不足，但是做的比较全面，四个审稿人意见都比较正面，一审四个审稿人，三个问题不大，reviewer4问题较多，一一解答并且修改，补了几个小实验，10天后修回。二审editor提了几点意见，重点说语言，两个审稿人没啥意见。找国外的朋友改了改。花了17天修改语言，修回后第二天直接接受，总共历时三个月，其中修稿差不多一个月，效率还可以。<br> 总结下：总共历时三个月。审稿人比较友好，提的问题也不难为人，编辑态度友好，编辑部效率较高，主要时间都花在了审稿上，二审时间较长。<br> 6.28 submitted<br> 6.28 editor assigned<br> 7.11 under review<br> 8.4 major revision<br> 8.15 submitted revised manuscript<br> 8.15 under review<br> 9.11 minor revision<br> 9.28 submitted revised manuscript<br> 9.29 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Mon Sep 30 10:37:18 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099271, encodeId=abfb10992e13b, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587723, encodeId=775458e7232a, content=请问这个杂志收费吗<span class="quote">zjqrae01 2014-07-09 13:33:00 发表:<br>今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。</span>, beContent=zjqrae01 2014-07-09 13:33:00 发表: 今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b195095115, createdName=145e0123m82暂无昵称, createdTime=Sun Mar 29 00:00:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854503, encodeId=bcfe8545033e, content=7.4 submitted<br> 8.25 major revision<br> 9.19 minor revision<br> 9.24 accepted<br> 两个审稿人，问题有点多，加编辑部指出一些语言方面的问题，总体感觉很友好。美国药学科学家协会的官方杂志之一，希望if稳定。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad75414098, createdName=ms658988217505615, createdTime=Fri Oct 25 19:52:53 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539451, encodeId=bc335394517c, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833325, encodeId=afcf833325da, content=速度很快，四十天就解决了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Aug 22 23:05:49 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504008, encodeId=ce2b50400880, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=529, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f06c87693, createdName=zjqrae01, createdTime=Wed Jul 09 13:33:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503302, encodeId=205e50330207, content=刚刚接受一篇，大修后主编直接接受！感觉主编、编辑、专家都很认真，很懂，提了很多问题一起探讨，是药剂学领域比较不错的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=463, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jun 03 10:39:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502240, encodeId=1d56502240cd, content=曾发过1篇 <br> <br> 俺不久前（其实“不久”也就一年）再次投稿这个杂志 <br> 近2个月后，两个Reviewers 一正一反 <br> 主编也不找仲裁 让俺大改 <br> 俺就大改回投 （1个月） <br> 3个月后，我发邮件询问二婶结果 主编说请耐心给他们一些时间 <br> 再过1个月 拒稿信件里面是唱反Reviewer的固执 <br> 外加主编的胡扯“我看稿件质量也一般，非常欢迎你下次再来搞”！ <br> <br> 我入，被这帮孙子搞晕了！ <br> 再也不跟他们玩了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:42:00 CST 2014, time=2014-04-08, status=1, ipAttribution=)]
    2017-07-18 chenyuming

    3分边缘，希望能维持稳定，略有上升也不错。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1099272, encodeId=697010992e2ce, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854040, encodeId=18ce854040d2, content=药剂学方向，纳米胶束。<br> 文章创新性自我感觉不足，但是做的比较全面，四个审稿人意见都比较正面，一审四个审稿人，三个问题不大，reviewer4问题较多，一一解答并且修改，补了几个小实验，10天后修回。二审editor提了几点意见，重点说语言，两个审稿人没啥意见。找国外的朋友改了改。花了17天修改语言，修回后第二天直接接受，总共历时三个月，其中修稿差不多一个月，效率还可以。<br> 总结下：总共历时三个月。审稿人比较友好，提的问题也不难为人，编辑态度友好，编辑部效率较高，主要时间都花在了审稿上，二审时间较长。<br> 6.28 submitted<br> 6.28 editor assigned<br> 7.11 under review<br> 8.4 major revision<br> 8.15 submitted revised manuscript<br> 8.15 under review<br> 9.11 minor revision<br> 9.28 submitted revised manuscript<br> 9.29 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Mon Sep 30 10:37:18 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099271, encodeId=abfb10992e13b, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587723, encodeId=775458e7232a, content=请问这个杂志收费吗<span class="quote">zjqrae01 2014-07-09 13:33:00 发表:<br>今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。</span>, beContent=zjqrae01 2014-07-09 13:33:00 发表: 今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b195095115, createdName=145e0123m82暂无昵称, createdTime=Sun Mar 29 00:00:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854503, encodeId=bcfe8545033e, content=7.4 submitted<br> 8.25 major revision<br> 9.19 minor revision<br> 9.24 accepted<br> 两个审稿人，问题有点多，加编辑部指出一些语言方面的问题，总体感觉很友好。美国药学科学家协会的官方杂志之一，希望if稳定。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad75414098, createdName=ms658988217505615, createdTime=Fri Oct 25 19:52:53 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539451, encodeId=bc335394517c, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833325, encodeId=afcf833325da, content=速度很快，四十天就解决了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Aug 22 23:05:49 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504008, encodeId=ce2b50400880, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=529, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f06c87693, createdName=zjqrae01, createdTime=Wed Jul 09 13:33:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503302, encodeId=205e50330207, content=刚刚接受一篇，大修后主编直接接受！感觉主编、编辑、专家都很认真，很懂，提了很多问题一起探讨，是药剂学领域比较不错的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=463, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jun 03 10:39:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502240, encodeId=1d56502240cd, content=曾发过1篇 <br> <br> 俺不久前（其实“不久”也就一年）再次投稿这个杂志 <br> 近2个月后，两个Reviewers 一正一反 <br> 主编也不找仲裁 让俺大改 <br> 俺就大改回投 （1个月） <br> 3个月后，我发邮件询问二婶结果 主编说请耐心给他们一些时间 <br> 再过1个月 拒稿信件里面是唱反Reviewer的固执 <br> 外加主编的胡扯“我看稿件质量也一般，非常欢迎你下次再来搞”！ <br> <br> 我入，被这帮孙子搞晕了！ <br> 再也不跟他们玩了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:42:00 CST 2014, time=2014-04-08, status=1, ipAttribution=)]
    2016-08-22 ms8714998894105664

    速度很快，四十天就解决了。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1099272, encodeId=697010992e2ce, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854040, encodeId=18ce854040d2, content=药剂学方向，纳米胶束。<br> 文章创新性自我感觉不足，但是做的比较全面，四个审稿人意见都比较正面，一审四个审稿人，三个问题不大，reviewer4问题较多，一一解答并且修改，补了几个小实验，10天后修回。二审editor提了几点意见，重点说语言，两个审稿人没啥意见。找国外的朋友改了改。花了17天修改语言，修回后第二天直接接受，总共历时三个月，其中修稿差不多一个月，效率还可以。<br> 总结下：总共历时三个月。审稿人比较友好，提的问题也不难为人，编辑态度友好，编辑部效率较高，主要时间都花在了审稿上，二审时间较长。<br> 6.28 submitted<br> 6.28 editor assigned<br> 7.11 under review<br> 8.4 major revision<br> 8.15 submitted revised manuscript<br> 8.15 under review<br> 9.11 minor revision<br> 9.28 submitted revised manuscript<br> 9.29 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Mon Sep 30 10:37:18 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099271, encodeId=abfb10992e13b, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587723, encodeId=775458e7232a, content=请问这个杂志收费吗<span class="quote">zjqrae01 2014-07-09 13:33:00 发表:<br>今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。</span>, beContent=zjqrae01 2014-07-09 13:33:00 发表: 今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b195095115, createdName=145e0123m82暂无昵称, createdTime=Sun Mar 29 00:00:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854503, encodeId=bcfe8545033e, content=7.4 submitted<br> 8.25 major revision<br> 9.19 minor revision<br> 9.24 accepted<br> 两个审稿人，问题有点多，加编辑部指出一些语言方面的问题，总体感觉很友好。美国药学科学家协会的官方杂志之一，希望if稳定。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad75414098, createdName=ms658988217505615, createdTime=Fri Oct 25 19:52:53 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539451, encodeId=bc335394517c, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833325, encodeId=afcf833325da, content=速度很快，四十天就解决了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Aug 22 23:05:49 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504008, encodeId=ce2b50400880, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=529, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f06c87693, createdName=zjqrae01, createdTime=Wed Jul 09 13:33:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503302, encodeId=205e50330207, content=刚刚接受一篇，大修后主编直接接受！感觉主编、编辑、专家都很认真，很懂，提了很多问题一起探讨，是药剂学领域比较不错的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=463, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jun 03 10:39:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502240, encodeId=1d56502240cd, content=曾发过1篇 <br> <br> 俺不久前（其实“不久”也就一年）再次投稿这个杂志 <br> 近2个月后，两个Reviewers 一正一反 <br> 主编也不找仲裁 让俺大改 <br> 俺就大改回投 （1个月） <br> 3个月后，我发邮件询问二婶结果 主编说请耐心给他们一些时间 <br> 再过1个月 拒稿信件里面是唱反Reviewer的固执 <br> 外加主编的胡扯“我看稿件质量也一般，非常欢迎你下次再来搞”！ <br> <br> 我入，被这帮孙子搞晕了！ <br> 再也不跟他们玩了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:42:00 CST 2014, time=2014-04-08, status=1, ipAttribution=)]
    2014-07-09 zjqrae01

    审稿速度:1.0 | 投稿命中率:75.0
    经验分享：今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1099272, encodeId=697010992e2ce, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854040, encodeId=18ce854040d2, content=药剂学方向，纳米胶束。<br> 文章创新性自我感觉不足，但是做的比较全面，四个审稿人意见都比较正面，一审四个审稿人，三个问题不大，reviewer4问题较多，一一解答并且修改，补了几个小实验，10天后修回。二审editor提了几点意见，重点说语言，两个审稿人没啥意见。找国外的朋友改了改。花了17天修改语言，修回后第二天直接接受，总共历时三个月，其中修稿差不多一个月，效率还可以。<br> 总结下：总共历时三个月。审稿人比较友好，提的问题也不难为人，编辑态度友好，编辑部效率较高，主要时间都花在了审稿上，二审时间较长。<br> 6.28 submitted<br> 6.28 editor assigned<br> 7.11 under review<br> 8.4 major revision<br> 8.15 submitted revised manuscript<br> 8.15 under review<br> 9.11 minor revision<br> 9.28 submitted revised manuscript<br> 9.29 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Mon Sep 30 10:37:18 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099271, encodeId=abfb10992e13b, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587723, encodeId=775458e7232a, content=请问这个杂志收费吗<span class="quote">zjqrae01 2014-07-09 13:33:00 发表:<br>今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。</span>, beContent=zjqrae01 2014-07-09 13:33:00 发表: 今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b195095115, createdName=145e0123m82暂无昵称, createdTime=Sun Mar 29 00:00:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854503, encodeId=bcfe8545033e, content=7.4 submitted<br> 8.25 major revision<br> 9.19 minor revision<br> 9.24 accepted<br> 两个审稿人，问题有点多，加编辑部指出一些语言方面的问题，总体感觉很友好。美国药学科学家协会的官方杂志之一，希望if稳定。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad75414098, createdName=ms658988217505615, createdTime=Fri Oct 25 19:52:53 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539451, encodeId=bc335394517c, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833325, encodeId=afcf833325da, content=速度很快，四十天就解决了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Aug 22 23:05:49 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504008, encodeId=ce2b50400880, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=529, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f06c87693, createdName=zjqrae01, createdTime=Wed Jul 09 13:33:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503302, encodeId=205e50330207, content=刚刚接受一篇，大修后主编直接接受！感觉主编、编辑、专家都很认真，很懂，提了很多问题一起探讨，是药剂学领域比较不错的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=463, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jun 03 10:39:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502240, encodeId=1d56502240cd, content=曾发过1篇 <br> <br> 俺不久前（其实“不久”也就一年）再次投稿这个杂志 <br> 近2个月后，两个Reviewers 一正一反 <br> 主编也不找仲裁 让俺大改 <br> 俺就大改回投 （1个月） <br> 3个月后，我发邮件询问二婶结果 主编说请耐心给他们一些时间 <br> 再过1个月 拒稿信件里面是唱反Reviewer的固执 <br> 外加主编的胡扯“我看稿件质量也一般，非常欢迎你下次再来搞”！ <br> <br> 我入，被这帮孙子搞晕了！ <br> 再也不跟他们玩了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:42:00 CST 2014, time=2014-04-08, status=1, ipAttribution=)]
    2014-06-03 匿名用户

    刚刚接受一篇，大修后主编直接接受！感觉主编、编辑、专家都很认真，很懂，提了很多问题一起探讨，是药剂学领域比较不错的杂志！

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1099272, encodeId=697010992e2ce, content=是否需要在讨论中说明文章局限性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854040, encodeId=18ce854040d2, content=药剂学方向，纳米胶束。<br> 文章创新性自我感觉不足，但是做的比较全面，四个审稿人意见都比较正面，一审四个审稿人，三个问题不大，reviewer4问题较多，一一解答并且修改，补了几个小实验，10天后修回。二审editor提了几点意见，重点说语言，两个审稿人没啥意见。找国外的朋友改了改。花了17天修改语言，修回后第二天直接接受，总共历时三个月，其中修稿差不多一个月，效率还可以。<br> 总结下：总共历时三个月。审稿人比较友好，提的问题也不难为人，编辑态度友好，编辑部效率较高，主要时间都花在了审稿上，二审时间较长。<br> 6.28 submitted<br> 6.28 editor assigned<br> 7.11 under review<br> 8.4 major revision<br> 8.15 submitted revised manuscript<br> 8.15 under review<br> 9.11 minor revision<br> 9.28 submitted revised manuscript<br> 9.29 accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf15414154, createdName=ms3508121495608353, createdTime=Mon Sep 30 10:37:18 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099271, encodeId=abfb10992e13b, content=文章的局限性是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587723, encodeId=775458e7232a, content=请问这个杂志收费吗<span class="quote">zjqrae01 2014-07-09 13:33:00 发表:<br>今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。</span>, beContent=zjqrae01 2014-07-09 13:33:00 发表: 今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b195095115, createdName=145e0123m82暂无昵称, createdTime=Sun Mar 29 00:00:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=854503, encodeId=bcfe8545033e, content=7.4 submitted<br> 8.25 major revision<br> 9.19 minor revision<br> 9.24 accepted<br> 两个审稿人，问题有点多，加编辑部指出一些语言方面的问题，总体感觉很友好。美国药学科学家协会的官方杂志之一，希望if稳定。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ad75414098, createdName=ms658988217505615, createdTime=Fri Oct 25 19:52:53 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539451, encodeId=bc335394517c, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833325, encodeId=afcf833325da, content=速度很快，四十天就解决了。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e005414046, createdName=ms8714998894105664, createdTime=Mon Aug 22 23:05:49 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504008, encodeId=ce2b50400880, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享：今年中了一篇，最高兴的是接受后马上就给DOI号了，小修，好象挺容易。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=529, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f06c87693, createdName=zjqrae01, createdTime=Wed Jul 09 13:33:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503302, encodeId=205e50330207, content=刚刚接受一篇，大修后主编直接接受！感觉主编、编辑、专家都很认真，很懂，提了很多问题一起探讨，是药剂学领域比较不错的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=463, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Jun 03 10:39:00 CST 2014, time=2014-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502240, encodeId=1d56502240cd, content=曾发过1篇 <br> <br> 俺不久前（其实“不久”也就一年）再次投稿这个杂志 <br> 近2个月后，两个Reviewers 一正一反 <br> 主编也不找仲裁 让俺大改 <br> 俺就大改回投 （1个月） <br> 3个月后，我发邮件询问二婶结果 主编说请耐心给他们一些时间 <br> 再过1个月 拒稿信件里面是唱反Reviewer的固执 <br> 外加主编的胡扯“我看稿件质量也一般，非常欢迎你下次再来搞”！ <br> <br> 我入，被这帮孙子搞晕了！ <br> 再也不跟他们玩了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=479, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:42:00 CST 2014, time=2014-04-08, status=1, ipAttribution=)]
    2014-04-08 匿名用户

    曾发过1篇

    俺不久前（其实“不久”也就一年）再次投稿这个杂志
    近2个月后，两个Reviewers 一正一反
    主编也不找仲裁 让俺大改
    俺就大改回投 （1个月）
    3个月后，我发邮件询问二婶结果 主编说请耐心给他们一些时间
    再过1个月 拒稿信件里面是唱反Reviewer的固执
    外加主编的胡扯“我看稿件质量也一般，非常欢迎你下次再来搞”！

    我入，被这帮孙子搞晕了！
    再也不跟他们玩了！

    0

共26条页码: 1/3页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分